Ana Catarina Silva

List of Publications by Citations

Source: https://exaly.com/author-pdf/920252/ana-catarina-silva-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 42 1,293 35 h-index g-index citations papers 1,562 4.2 4.94 54 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
42	Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011 , 86, 158-65	6	188
41	Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 112, 159-167	5.1	176
40	Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013 , 111, 755-63	6	101
39	Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2012 , 436, 798-805	6.5	80
38	Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. <i>Journal of Controlled Release</i> , 2019 , 295, 187-200	11.7	67
37	Solid lipid nanoparticles (SLN)based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2012 , 93, 241-8	6	65
36	Lipid Nanoparticles for Nasal/Intranasal Drug Delivery. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2017 , 34, 257-282	2.8	51
35	Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. <i>Current Medicinal Chemistry</i> , 2012 , 19, 4495-510	4.3	51
34	Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2014 , 17, 278-93	3.4	47
33	Improving oral absorption of Salmon calcitonin by trimyristin lipid nanoparticles. <i>Journal of Biomedical Nanotechnology</i> , 2009 , 5, 76-83	4	39
32	Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. <i>Die Pharmazie</i> , 2009 , 64, 177-82	1.5	32
31	Design, characterization, and clinical evaluation of argan oil nanostructured lipid carriers to improve skin hydration. <i>International Journal of Nanomedicine</i> , 2014 , 9, 3855-64	7.3	29
30	Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of studies. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 925-940	15.5	29
29	Characterization and biocompatibility evaluation of cutaneous formulations containing lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2017 , 519, 373-380	6.5	28
28	Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia. <i>Current Pharmaceutical Design</i> , 2013 , 19, 7185-95	3.3	26
27	Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists. <i>Current Drug Metabolism</i> , 2015 , 16, 3-16	3.5	22
26	Evaluation of the biocompatibility and skin hydration potential of vitamin E-loaded lipid nanosystems formulations: In vitro and human in vivo studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019 , 179, 242-249	6	21

(2019-2020)

25	Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters. <i>Pharmaceutics</i> , 2020 , 12,	6.4	20	
24	Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers. <i>Current Pharmaceutical Biotechnology</i> , 2015 , 16, 955-65	2.6	20	
23	Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020 , 28, 102206	6	19	
22	Biosimilar medicines used for cancer therapy in Europe: a review. <i>Drug Discovery Today</i> , 2019 , 24, 293-2	2 99 .8	17	
21	Risperidone Release from Solid Lipid Nanoparticles (SLN): Validated HPLC Method and Modelling Kinetic Profile. <i>Current Pharmaceutical Analysis</i> , 2012 , 8, 307-316	0.6	16	
20	Lipid nanoparticles for the delivery of biopharmaceuticals. <i>Current Pharmaceutical Biotechnology</i> , 2015 , 16, 291-302	2.6	15	
19	Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems. <i>Current Medicinal Chemistry</i> , 2016 , 23, 3618-3631	4.3	13	
18	Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases. <i>Current Pharmaceutical Design</i> , 2017 ,	3.3	13	
17	Biotechnology Applied to Cosmetics and Aesthetic Medicines. <i>Cosmetics</i> , 2020 , 7, 33	2.7	13	
16	Scaffolds for Bone Regeneration: State of the Art. Current Pharmaceutical Design, 2016, 22, 2726-36	3.3	12	
15	Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels. <i>International Journal of Nanomedicine</i> , 2021 , 16, 4373-4390	7.3	12	
14	In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). <i>Pharmaceuticals</i> , 2021 , 14,	5.2	12	
13	Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles. <i>Current Pharmaceutical Biotechnology</i> , 2015 , 16, 940-54	2.6	10	
12	Cytokines and Growth Factors. Advances in Biochemical Engineering/Biotechnology, 2020 , 171, 87-113	1.7	9	
11	Sudden cardiac death in young adult. Cardiovascular Toxicology, 2014, 14, 379-86	3.4	6	
10	Lipid Nanoparticles Containing Mixtures of Antioxidants to Improve Skin Care and Cancer Prevention <i>Pharmaceutics</i> , 2021 , 13,	6.4	6	
9	Pessaries containing nanostructured lipid carriers (NLC) for prolonged vaginal delivery of progesterone. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 153, 105475	5.1	5	
8	Adhesion in Dentin Prepared with Er,Cr:YSGG Laser: Systematic Review. <i>Contemporary Clinical Dentistry</i> , 2019 , 10, 129-134	0.6	4	

7	Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells. <i>International Journal of Pharmaceutics</i> , 2021 , 607, 120933	6.5	3
6	Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies <i>International Journal of Pharmaceutics</i> , 2022 , 620, 121720	6.5	3
5	Hormones, Blood Products, and Therapeutic Enzymes. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2020 , 171, 115-153	1.7	1
4	Insights on the Formulation of Recombinant Proteins. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2020 , 171, 23-54	1.7	0
3	Hematopoietic Growth Factors 2021 , 775-779		
2	Application of the Quality-by-Design (QbD) Approach to Improve the Nose-to-Brain Delivery of Diazepam-Loaded Nanostructured Lipid Carriers (NLCs). <i>Proceedings (mdpi)</i> , 2021 , 78, 40	0.3	
1	Thermosensitive Nasal In Situ Gels of Lipid-Based Nanosystems to Improve the Treatment of Alzheimer Disease. <i>Proceedings (mdpi)</i> , 2021 , 78, 37	0.3	